1-hexadecyl-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl]-sn-glycero-3-phosphocholine

Metabolite details

Identifier

QQQQNYAHSSIZBU-HIQXTUQZSA-N

InChI Key

QQQQNYAHSSIZBU-HIQXTUQZSA-N

IUPAC name

(2R)-2-{[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy}-3-(hexadecyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate

Preferred name

1-hexadecyl-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl]-sn-glycero-3-phosphocholine

INN name

—

Synonym

PC(O-16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

ChEBI

CHEBI:86248

Reactome pathways

• No Reactome pathways listed for this metabolite.

Observed in studies

• Large-Scale Plasma Analysis Revealed New Mechanisms and Molecules Associated with the Host Response to SARS-CoV-2.
• Physiological extremes of the human blood metabolome: A metabolomics analysis of highly glycolytic, oxidative, and anabolic athletes
• A multi-omics approach to study peroxisome proliferator-activated receptor mediated regulation of lipid metabolism in Atlantic cod (Gadus morhua)
• Metabolic Dynamics of In Vitro CD8+ T Cell Activation.
• Metabolic characterization of the natural progression of chronic hepatitis B (Lipid assays).
• Metabolic profilings of rat INS-1 β-cells under changing levels of essential amino acids
• Dysregulation of lipid metabolism and pathological inflammation in patients with COVID-19

Observed in differential profiles

• non_COVID_19_healthy_vs_non_critical_COVID_19
• Control_Baseline_vs_Control_Post-Exercise
• Control_Plasma_vs_WY-14,643_Plasma
• G3_Experimental_Sample_0h_vs_G11_Experimental_Sample_96h
• Control_vs_Immune_Tolerant
• Control_vs_Immune_Tolerant
• Control_vs_Immune_Tolerant
• G1_Control_vs_G2_Arginine_Addition
• Mild_vs_Severe